The global market for human leukocyte antigens (HLAs) typing is driven by factors such as increased funding for research, growing numbers of transplantation procedures, technological advancements, and the potential in emerging markets. HLA typing transplant diagnostics services are vital for successful organ and tissue transplantation, ensuring accurate donor-recipient matching, reducing rejection risks, and improving transplant success rates. Overall, the market presents lucrative opportunities for innovation and expansion, with a focus on addressing the challenges and improving accessibility to transplant diagnostics services.
Access Full Report: https://www.databridgemarketresearch.com/reports/global-hla-typing-transplant-diagnostics-services-market
Data Bridge Market Research analyses that the Global Human Leukocyte Antigens (HLAs) Typing Transplant Diagnostics Services Market is expected to grow at a CAGR of 9.45% in the forecast period of 2022 to 2029. The growing number of organ transplantation procedures worldwide is a major driver for the HLAs typing transplant diagnostics services market. HLAs typing is essential for matching donors and recipients to ensure successful transplantation outcomes.
Key Findings of the Study
Rising awareness and access to transplantation is expected to drive the market's growth rate
The rising awareness and improved access to transplantation services have significantly contributed to the increased demand for HLAs typing and transplant diagnostics services. Greater awareness among the general population about the life-saving potential of organ transplantation has led to a higher acceptance and willingness to undergo these procedures. Additionally, advancements in healthcare infrastructure and the establishment of specialized transplantation centers have made these services more accessible, further driving the demand for HLAs typing and transplant diagnostics.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014-2019)
|
|
Segments Covered
|
Product and Services (Instruments, Reagents and Consumables, Software and Services), Application (Diagnostics and Research), End-user (Hospitals, Academic and Research Institutes), End-User (Direct Tender, Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Others), Technology (polymerase chain reaction and Next-Generation Sequencing)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
|
|
Market Players Covered
|
Thermo Fisher Scientific Inc. (U.S.), AbbVie Inc. (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Illumina, Inc. (U.S.), QIAGEN (Germany), Immucor, Inc. (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Luminex Corporation (U.S.), CareDx, Inc. (U.S.), GenDx (Netherlands), Voden Medical Instruments S.p.a. (Italy), TBG Diagnostics Limited (Australia), ProImmune Ltd (U.K.), Pacific Biosciences of California, Inc. (U.S.), Omixon Inc. (Hungary), omicX (France), MC Diagnostics Ltd (South Korea), Integrated Gulf Biosystems (United Arab Emirates), InGen (South Korea), and Hologic, Inc. (U.S.) among others
|
|
Data Points Covered in the Report
|
In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
|
Segment Analysis:
The human leukocyte antigens (HLAs) typing transplant diagnostics services market is segmented on the basis of product and services, application, end-user and technology.
- On the basis of product and services, the human leukocyte antigens (HLAs) typing transplant diagnostics services market is segmented into instruments, reagents and consumables, software, and services.
- On the basis of application, the human leukocyte antigens (HLAs) typing transplant diagnostics services market is segmented into diagnostics and research.
- On the basis of end-user, the human leukocyte antigens (HLAs) typing transplant diagnostics services market is segmented into hospitals, and academic and research institutes.
- On the basis of technology into polymerase chain reaction and next-generation sequencing.
Major Players
Data Bridge market research recognizes the following companies as the major human leukocyte antigens (HLAs) typing transplant diagnostics services market players in human leukocyte antigens (HLAs) typing transplant diagnostics services market are Bio-Rad Laboratories, Inc. (U.S.), Luminex Corporation (U.S.), CareDx, Inc. (U.S.), GenDx (Netherlands), Voden Medical Instruments S.p.a. (Italy), TBG Diagnostics Limited (Australia), ProImmune Ltd (U.K.), Pacific Biosciences of California, Inc. (U.S.), Omixon Inc. (Hungary), omicX (France), MC Diagnostics Ltd (South Korea)
Market Development
- In 2022, Mylab Discovery Solutions launched DiscoverSeries HLAB*27 detection kit, an in-vitro diagnostic test for Ankylosing Spondylitis (AS).
- In 2022, Genome Diagnostics (GenDx), a Dutch molecular diagnostics firm received approval from Canadian regulators for the invitro diagnostic use of its NGSgo-MX11-3 human leukocyte antigen genotyping test.
Regional Analysis
Geographically, the countries covered in the human leukocyte antigens (HLAs) typing transplant diagnostics services market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
As per Data Bridge Market Research analysis:
North America is the dominant region in human leukocyte antigens (HLAs) typing transplant diagnostics services market during the forecast period 2022-2029
North America's dominance in the human leukocyte antigens (HLAs) typing transplant diagnostics services market is driven by factors such as increased research and development investments, technological advancements in transplant diagnostics, and a high volume of organ transplantation procedures. The region's focus on advancing transplant-related technologies and infrastructure contributes to its continued dominance and growth in the market during the forecast period.
Asia-Pacific is estimated to be the fastest growing region in human leukocyte antigens (HLAs) typing transplant diagnostics services market the forecast period 2022-2029
Asia-Pacific is expected to experience significant growth in the human leukocyte antigens (HLAs) typing transplant diagnostics services market due to several factors. These include increased government spending on the healthcare sector, a growing geriatric population, adoption of advanced transplant diagnostic technologies, and rising personal disposable income. These trends create a favorable environment for the expansion of transplant diagnostics services in the region, leading to a high growth rate during the forecast period.
For more detailed information about the human leukocyte antigens (HLAS) typing transplant diagnostics services market report, click here – https://www.databridgemarketresearch.com/reports/global-hla-typing-transplant-diagnostics-services-market
